AMI ORGANICS Ltd IPO ANALYSIS
Ami organics is one of the leading research and development driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical ingredients (API) for New Chemical Entities, and material for agrochemicals and fine chemicals.
The company has developed over 450 pharma intermediates across 17 key therapeutic areas i.e. anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant. It supplies its products to more than 150 customers (including international customers) directly in India and in 25 countries overseas i.e. Europe, USA, China, Israel, Japan, Latin America, etc. Laurus Labs, Cadila Healthcare, Cipla Ltd are some of the domestic customers whereas Organike s.r.l.a. Socio Unico, Fermion Oly, Medichem S.A. and Midas Pharma GmbH are some of the international customers.
The company has three manufacturing facilities in Gujarat situated at Sachin, Ankleshwar & Jhagadia, with an aggregate installed capacity of 6,060 MTPA. It is one of the leading manufacturers of certain Pharma Intermediates i.e. Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban also having Strong and diversified product portfolio with 450+ Pharma Intermediates.
For FY 21, the company had total assets of Rs 4132.68 million and a Revenue of Rs. 3419.88 million. Ami Organics revenue has risen from 2019 to 2021. The company’s profit rose from 232.95 million in 2019 to 539.99 million in 2021.
The Ami Organics IPO open date is Sep 1, 2021, and the close date is Sep 3, 2021. The issue may list on Sep 14, 2021. The issue size of the IPO is supposed to be 569.64 Cr. Considering the price and future scope of the stock, it is suggested to invest in Ami Organics.
